stockportfolio.pro
ORIC Pharmaceuticals, Inc. (ORIC)
Healthcare · Biotechnology · NasdaqGS
ORIC Pharmaceuticals, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-21.36M | $-26.88M | $-73.70M | $-78.72M | $-89.12M | $-100.70M | $-127.85M | $-129.47M |
| Net margin | — | — | — | — | — | — | — | — |
Source: ORIC Pharmaceuticals, Inc. SEC filings (10-K).
Explore 8 years of ORIC Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ORIC in your portfolio →
ORIC Pharmaceuticals, Inc. financial history by metric
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. — frequently asked questions
What is ORIC Pharmaceuticals, Inc.'s revenue?
ORIC Pharmaceuticals, Inc. (ORIC) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is ORIC Pharmaceuticals, Inc. profitable?
No — ORIC reported a net loss of $-129.47M in fiscal 2025.
What is ORIC's P/E ratio?
ORIC Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does ORIC Pharmaceuticals, Inc. have?
As of fiscal year 2025, ORIC carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ORIC Pharmaceuticals, Inc.'s market cap?
ORIC Pharmaceuticals, Inc. (ORIC) has a market capitalization of about $793.46M, based on the latest data in our nightly-refreshed cache.
When does ORIC Pharmaceuticals, Inc.'s fiscal year end?
ORIC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ORIC Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.